Treatment of severe acute graft-versus-host disease with anti-thymocyte globulin (Q34271895)

1 August 2017

1 reference

title

Treatment of severe acute graft-versus-host disease with anti-thymocyte globulin (English)

1 reference

1 August 2017

0 references

Remberger M

1 reference

1 August 2017

Aschan J

1 reference

1 August 2017

Barkholt L

1 reference

1 August 2017

Tollemar J

1 reference

1 August 2017

Ringdén O

1 reference

1 August 2017

language of work or name

1 reference

1 June 2001

1 reference

1 August 2017

published in

Clinical Transplantation

1 reference

1 August 2017

1 reference

1 August 2017

1 reference

1 August 2017

page(s)

147-153

1 reference

Dysregulation of cytokines during graft-versus-host disease

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2001.150301.X

Risk factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single centre analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2001.150301.X

Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2001.150301.X

Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings. Beneficial effect of a protective environment

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2001.150301.X

7 January 2021

Marrow transplantation from HLA-matched unrelated donors for treatment of hematologic malignancies

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2001.150301.X

7 January 2021

Death by graft-versus-host disease associated with HLA mismatch, high recipient age, low marrow cell dose, and splenectomy

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2001.150301.X

7 January 2021

Treatment of graft-versus-host disease by extracorporeal photochemotherapy: a pilot study

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2001.150301.X

7 January 2021

Methoxsalen and ultraviolet A radiation in treatment of chronic cutaneous graft-versus-host reaction

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2001.150301.X

7 January 2021

Thalidomide for graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2001.150301.X

7 January 2021

Treatment of graft-versus-host disease in human allogeneic marrow graft recipients: a randomized trial comparing antithymocyte globulin and corticosteroids

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2001.150301.X

7 January 2021

HLA-DR-DQ haplotypes defined by restriction fragment analysis. Correlation to serology

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2001.150301.X

7 January 2021

HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2001.150301.X

7 January 2021

Effect on cytokine release and graft-versus-host disease of different anti-T cell antibodies during conditioning for unrelated haematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2001.150301.X

7 January 2021

Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2001.150301.X

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2001.150301.X

7 January 2021

Immunological reconstitution following bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2001.150301.X

7 January 2021

Recovery of in vivo cellular immunity after human marrow grafting. Influence of time postgrafting and acute graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2001.150301.X

7 January 2021

Pharmacokinetics, safety and preliminary clinical experiences using foscarnet in the treatment of cytomegalovirus infections in bone marrow and renal transplant recipients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2001.150301.X

7 January 2021

Safety and efficacy of liposomal amphotericin B in allogeneic bone marrow transplant recipients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2001.150301.X

7 January 2021

PCR and other non-culture methods for diagnosis of invasive Candida infections in allogeneic bone marrow and solid organ transplant recipients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2001.150301.X

7 January 2021

Low-dose cyclosporine of short duration increases the risk of mild and moderate GVHD and reduces the risk of relapse in HLA-identical sibling marrow transplant recipients with leukaemia

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2001.150301.X

7 January 2021

Risk factors for acute graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2001.150301.X

7 January 2021

Antileukemic Effect of Graft-versus-Host Disease in Human Recipients of Allogeneic-Marrow Grafts

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2001.150301.X

7 January 2021

Interleukin-11 promotes T cell polarization and prevents acute graft-versus-host disease after allogeneic bone marrow transplantation.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2001.150301.X

7 January 2021

T cell mixed chimerism is significantly correlated to a decreased risk of acute graft-versus-host disease after allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2001.150301.X

7 January 2021

10.1034/J.1399-0012.2001.150301.X

Identifiers

DOI

1 reference

1 August 2017

1 reference